A metabolic-dysfunction associated steatotic liver acinus biomimetic induces pancreatic islet dysfunction in a coupled microphysiology system

Julio Aleman,K Ravikumar,Connor Wiegand,Mark E. Schurdak,Lawrence Vernetti,Dillon Gavlock,Celeste Reese,Richard DeBiasio,Greg LaRocca,Yulder Daniel Angarita,Albert Gough,Alejandro Soto-Gutierrez,Jaideep Behari,Vijay Yechoor,Mark T. Miedel,Andrew M. Stern,Ipsita Banerjee,D. Lansing Taylor

DOI: https://doi.org/10.1101/2024.04.22.590598

2024-04-30

Abstract:Preclinical and clinical studies suggest that lipid-induced hepatic insulin resistance is a primary defect that predisposes to dysfunction in pancreatic islets, implicating a perturbed liver-pancreas axis underlying the comorbidity of T2DM and MASLD. To investigate this hypothesis, we developed a human biomimetic microphysiological system (MPS) coupling our vascularized liver acinus MPS (vLAMPS) with primary islets on a chip (PANIS) enabling MASLD progression and islet dysfunction to be quantitatively assessed. The modular design of this system (vLAMPS-PANIS) allows intra-organ and inter-organ dysregulation to be deconvoluted. When compared to normal fasting (NF) conditions, under early metabolic syndrome (EMS) conditions, the standalone vLAMPS exhibited characteristics of early stage MASLD, while no significant differences were observed in the standalone PANIS. In contrast, with EMS, the coupled vLAMPS-PANIS exhibited a perturbed islet-specific secretome and a significantly dysregulated glucose stimulated insulin secretion (GSIS) response implicating direct signaling from the dysregulated liver acinus to the islets. Correlations between several pairs of a vLAMPS-derived and a PANIS-derived secreted factors were significantly altered under EMS, as compared to NF conditions, mechanistically connecting MASLD and T2DM associated hepatic factors with islet-derived GLP-1 synthesis and regulation. Since vLAMPS-PANIS is compatible with patient–specific iPSCs, this platform represents an important step towards addressing patient heterogeneity, identifying complex disease mechanisms, and advancing precision medicine.

Bioengineering

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore how metabolic - dysfunction - associated steatotic liver disease (MASLD) affects islet function through the liver - pancreas axis, thereby leading to type 2 diabetes mellitus (T2DM). Specifically, the researchers developed a coupled human microphysiological system (MPS), combining the vascularized liver acinus MPS (vLAMPS) with primary islets on a chip (PANIS) to simulate the development of MASLD under early metabolic syndrome (EMS) conditions and its impact on islet function. Through this system, they hope to reveal how MASLD directly affects the function of islets through specific secreted factors, especially in the context of hyperglycemia and hyperinsulinemia, and how these factors exacerbate β - cell dysfunction.

The main objectives of the paper include:
1. **Verify the hypothesis**: By comparing the functional differences between the independently operating vLAMPS and PANIS modules and the coupled system, verify whether early MASLD can directly induce islet dysfunction.
2. **Identify the mechanism**: By analyzing the interactions of secreted factors between the vLAMPS and PANIS modules, identify how specific liver - derived factors affect islet function.
3. **Evaluate heterogeneity**: By using patient - specific induced pluripotent stem cells (iPSCs), evaluate the heterogeneity between different patients and provide a basis for precision medicine.

The research results show that under early metabolic syndrome conditions, the vLAMPS module in the coupled system exhibits characteristics of MASLD, such as steatosis and impaired insulin signaling, while the PANIS module shows changes in the islet - specific secretome and significant abnormal glucose - stimulated insulin secretion (GSIS) responses. These findings support the hypothesis that MASLD directly affects islet function through specific liver - derived factors.